Bayat Allan, Pendziwiat Manuela, Obersztyn Ewa, Goldenberg Paula, Zacher Pia, Döring Jan Henje, Syrbe Steffen, Begtrup Amber, Borovikov Artem, Sharkov Artem, Karasińska Aneta, Giżewska Maria, Mitchell Wendy, Morava Eva, Møller Rikke S, Rubboli Guido
Institute for Regional Health Services, University of Southern Denmark, Odense, Denmark.
Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Dianalund, Denmark.
Front Genet. 2021 May 11;12:663643. doi: 10.3389/fgene.2021.663643. eCollection 2021.
The two aims of this study were (i) to describe and expand the phenotypic spectrum of deficiency in affected individuals harboring the c.1582G>A; p.Val528Met or the c.1580A > G; p.Asn527Ser variant in either homozygous or compound heterozygous state, and (ii) to identify potential genotype-phenotype correlations and any differences in disease severity among individuals with and without the variants. The existing literature was searched to identify individuals with and without the two variants. A detailed phenotypic assessment was performed of 25 individuals (both novel and previously published) with the two variants. We compared severity of disease between individuals with and without these variants. Twenty-four individuals carried the variant Val528Met in either homozygous or compound heterozygous state, and one individual displayed the Asn527Ser variant in a compound heterozygous state. Disease severity in the individual with the Asn527Ser variant was compatible with that in the individuals harboring the Val528Met variant. While individuals without the Asn527Ser or Val528Met variant had focal epilepsy, profound developmental delay (DD), and risk of premature death, those with either of the two variants had moderate to severe DD and later onset of epilepsy with both focal and generalized seizures. Individuals homozygous for the Val528Met variant generally became seizure-free on monotherapy with antiepileptic drugs, compared to other individuals who were pharmaco-resistant. Two patients were diagnosed with myoclonic-atonic seizures, and a single patient was diagnosed with eyelid myoclonia. Our comprehensive analysis of this large cohort of previously published and novel individuals with variants broadens the phenotypical spectrum and shows that both Asn527Ser and Val528Met are associated with a milder phenotype and less severe outcome. Our data show that is a new candidate gene for myoclonic atonic epilepsy. Our genotype-phenotype correlation will be useful for future genetic counseling. Natural history studies of this mild spectrum of related disorder may shed light on hitherto unknown aspects of this rare disorder.
(i)描述和扩展纯合或复合杂合状态下携带c.1582G>A;p.Val528Met或c.1580A>G;p.Asn527Ser变体的受影响个体的缺陷表型谱,以及(ii)识别潜在的基因型-表型相关性以及有和没有这些变体的个体之间疾病严重程度的任何差异。检索现有文献以识别有和没有这两种变体的个体。对25名携带这两种变体的个体(包括新发现的和先前已发表的)进行了详细的表型评估。我们比较了有和没有这些变体的个体之间的疾病严重程度。24名个体以纯合或复合杂合状态携带Val528Met变体,1名个体以复合杂合状态显示Asn527Ser变体。携带Asn527Ser变体的个体的疾病严重程度与携带Val528Met变体的个体的疾病严重程度相当。没有Asn527Ser或Val528Met变体的个体患有局灶性癫痫、严重发育迟缓(DD)和过早死亡风险,而具有这两种变体之一的个体患有中度至重度DD,癫痫发作较晚,包括局灶性和全身性发作。与其他药物抵抗的个体相比,Val528Met变体纯合的个体通常在抗癫痫药物单药治疗后无癫痫发作。两名患者被诊断为肌阵挛-失张力发作,一名患者被诊断为眼睑肌阵挛。我们对这一大批先前已发表的和新发现的携带变体个体的综合分析拓宽了表型谱,并表明Asn527Ser和Val528Met均与较轻的表型和不太严重的结果相关。我们的数据表明,[基因名称]是肌阵挛失张力癫痫的一个新候选基因。我们的基因型-表型相关性将有助于未来的遗传咨询。对这种轻度相关疾病谱的自然史研究可能会揭示这种罕见疾病迄今未知的方面。